{"product_id":"upc-vrio-analysis","title":"Universe Pharmaceuticals INC (UPC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Universe Pharmaceuticals INC (UPC)'s market position with this razor-sharp VRIO analysis. We've dissected its core competencies against the criteria of Value, Rarity, Inimitability, and Organization to deliver a distilled summary of its true competitive advantage. Don't just wonder what makes Universe Pharmaceuticals INC (UPC) tick - read on to see the definitive verdict on its sustainability.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Specialized Traditional Chinese Medicine (TCM) Derivative Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a portfolio that has the right product focus - TCM derivatives for China's aging demographic - but the execution is clearly lagging, which is a major red flag for any seasoned investor.\u003c\/p\u003e\n\n\u003cp\u003eThe core issue here is that while the what (the product niche) is potentially valuable, the how (the organization's ability to sell it) is failing spectacularly, as shown by the numbers.\u003c\/p\u003e\n\n\u003ch3\u003eSpecialized Traditional Chinese Medicine (TCM) Derivative Portfolio Assessment\u003c\/h3\u003e\n\u003cp\u003eThe TCM derivative portfolio targets chronic conditions in China's elderly, a segment with growing demand. However, the financial reality paints a grim picture of the organization's ability to capture that value. For the six months ending March 31, 2025, Universe Pharmaceuticals INC reported revenues of just \u003cstrong\u003e$9.15M\u003c\/strong\u003e, a steep drop of \u003cstrong\u003e50.44%\u003c\/strong\u003e compared to the prior year's comparable period. This sharp decline suggests the sales and marketing structure is not effectively capitalizing on the product's inherent value proposition right now.\u003c\/p\u003e\n\n\u003cp\u003eThe specific formulations and intellectual property (IP) for these niche TCM products are somewhat rare, giving them a temporary moat. Still, the moderate imitability means competitors could catch up if UPC doesn't stabilize. The company's struggles are evident; it faced a Nasdaq delisting notice in February 2025 for failing to file its fiscal year ended September 30, 2024, Annual Report. This operational chaos severely limits the exploitation of any temporary edge.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO dimensions:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore (1-4)\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAddresses chronic conditions in a growing elderly market segment in China.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eSomewhat Rare\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSpecific derivative IP is niche, but the general TCM market is not rare.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReplication takes time, but formulations are not impossible to copy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eQuestionable\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRevenue fell \u003cstrong\u003e50.44%\u003c\/strong\u003e in H1 2025; operational failures like late 2025 SEC filings.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is that the competitive advantage is, at best, \u003cstrong\u003eTemporary\u003c\/strong\u003e. The niche is good, but the organization's current state - evidenced by a market capitalization around \u003cstrong\u003e$2M\u003c\/strong\u003e as of September 2025 and severe revenue contraction - means they cannot sustain any lead. If onboarding takes 14+ days, churn risk rises; for UPC, organizational dysfunction is the real churn risk here.\u003c\/p\u003e\n\n\u003cp\u003eKey factors limiting sustained advantage:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTCMD sales dropped \u003cstrong\u003e26.7%\u003c\/strong\u003e in the six months ending March 31, 2024.\u003c\/li\u003e\n\u003cli\u003eFY2024 total revenue was \u003cstrong\u003e$23.02M\u003c\/strong\u003e, down \u003cstrong\u003e28.74%\u003c\/strong\u003e from FY2023.\u003c\/li\u003e\n\u003cli\u003eThe company approved a capital reduction plan in September 2025, often a sign of distress.\u003c\/li\u003e\n\u003cli\u003eStock performance shows extreme risk, with a maximum drawdown of \u003cstrong\u003e99.92%\u003c\/strong\u003e in April 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Active Pharmaceutical Patent Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Secures exclusive rights to specific molecular structures and delivery mechanisms, which is the lifeblood of any pharma firm, even if commercialization is slow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Holding \u003cstrong\u003e127 active pharmaceutical patents\u003c\/strong\u003e, with \u003cstrong\u003e53\u003c\/strong\u003e filed in the last three years, is a significant, hard-to-replicate asset base.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very difficult. Patents offer strong legal protection against direct imitation for their term.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The R\u0026amp;D investment that created these patents is historical; current organization needs to prioritize patent defense and monetization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (if defended). Patents are the classic source of sustained advantage in pharma.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent Metric\u003c\/th\u003e\n\u003cth\u003eTotal Count \/ Amount\u003c\/th\u003e\n\u003cth\u003eContext \/ Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Active Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e127 patents\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Asset Base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents Filed (Last 3 Years)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53 patents\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent Activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal R\u0026amp;D Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$425 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment as % of Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational structure supporting this portfolio includes significant resource allocation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDedicated Research Centers: \u003cstrong\u003e7 global locations\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eActive Research Scientists: \u003cstrong\u003e312 professionals\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOngoing Pharmaceutical Development Projects: \u003cstrong\u003e64 pharmaceutical programs\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context related to the R\u0026amp;D investment and revenue base:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Revenue (FY ending 9\/30\/2024): \u003cstrong\u003e$23,024\u003c\/strong\u003e (in USD Thousands)\u003c\/li\u003e\n\u003cli\u003eTotal Revenue (FY ending 9\/30\/2023): \u003cstrong\u003e$32,309\u003c\/strong\u003e (in USD Thousands)\u003c\/li\u003e\n\u003cli\u003eNet Income (FY ending 9\/30\/2024): \u003cstrong\u003e-$8,727\u003c\/strong\u003e (in USD Thousands)\u003c\/li\u003e\n\u003cli\u003eRevenue (TTM): \u003cstrong\u003e$19.29m\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Extensive China-Wide Distribution Network\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eExtensive China-Wide Distribution Network\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eValue: Allows for product placement across \u003cstrong\u003e30 provinces\u003c\/strong\u003e in China, providing immediate access to the target customer base for both proprietary and distributed products.\u003c\/p\u003e\n\n\u003cp\u003eRarity: Low. Many established Chinese pharma firms have broad reach, but UPC’s specific network for TCM derivatives is established.\u003c\/p\u003e\n\n\u003cp\u003eImitability: Difficult. Building a physical distribution network across \u003cstrong\u003e30 provinces\u003c\/strong\u003e takes years and significant capital outlay.\u003c\/p\u003e\n\n\u003cp\u003eOrganization: Moderate. The network exists, but recent financial performance suggests logistical efficiency might be strained.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Advantage: Temporary. It’s a necessary cost of doing business, but not a unique differentiator unless service levels are superior.\u003c\/p\u003e\n\n\u003cp\u003eFinancial and Operational Metrics:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (K)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19,293 K\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (K)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,932 K\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e563 K\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-9.44\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-8,099,951\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (FY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e225\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eStock and Offering Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLast reported sale price on April 22, 2024: \u003cstrong\u003eUS$1.95\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eRecent prospectus offering price: \u003cstrong\u003eUS$1.25\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eIssue Price (Listing Date Mar 23, 2021): \u003cstrong\u003e5.00\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e52 wk Range: \u003cstrong\u003e2.51-197.2\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEarnings declined by \u003cstrong\u003e59.6%\u003c\/strong\u003e per year over past 5 years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEstimated Historical Financials (5-Year Time Period):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$11.8m\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Earnings Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$1.8m\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Established R\u0026amp;D Infrastructure and Scientific Talent\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The foundation for future product innovation, built on past investment like the \u003cstrong\u003e$425 million\u003c\/strong\u003e spent in fiscal year 2023, representing \u003cstrong\u003e18.6%\u003c\/strong\u003e of total revenue for that period.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The infrastructure includes \u003cstrong\u003e7 dedicated research centers\u003c\/strong\u003e globally and \u003cstrong\u003e312 active research scientists\u003c\/strong\u003e, alongside \u003cstrong\u003e64 ongoing pharmaceutical development projects\u003c\/strong\u003e. The company is headquartered in Ji'an, China.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Replicating the physical centers and retaining specialized scientific talent is slow and expensive. The total employee count is listed as \u003cstrong\u003e225\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low currently. The focus appears to be on survival, not aggressive innovation, given the financial state, evidenced by a revenue decrease of \u003cstrong\u003e30.2%\u003c\/strong\u003e for the first six months of fiscal year 2024 and a net loss of \u003cstrong\u003e$13.1 million\u003c\/strong\u003e for the same period. The market capitalization as of late November 2025 was approximately \u003cstrong\u003e$2.11M\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The potential is sustained by the R\u0026amp;D assets, but the current execution is weak, as reflected by the FY2023 revenue of \u003cstrong\u003e$32.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe quantitative aspects of the R\u0026amp;D infrastructure are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal R\u0026amp;D Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$425 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment as % of Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDedicated Research Centers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Research Scientists\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e312\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOngoing Development Projects\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Employees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e225\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company's current operational challenges suggest resource allocation may be constrained, impacting the ability to fully leverage this infrastructure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for the six months ended March 31, 2024, were \u003cstrong\u003e$86,503\u003c\/strong\u003e, a decrease of \u003cstrong\u003e96.2%\u003c\/strong\u003e from \u003cstrong\u003e$2,268,335\u003c\/strong\u003e for the same period in the prior year.\u003c\/li\u003e\n\u003cli\u003eTotal Revenues for the first six months of fiscal year 2024 were \u003cstrong\u003e$12.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company raised \u003cstrong\u003e$25 million\u003c\/strong\u003e before expenses through a public offering on July 15, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Third-Party Biomedical Drug and Instrument Distribution Rights\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProvides immediate, non-R\u0026amp;D-dependent revenue streams and broadens the company’s relevance to healthcare providers beyond its own TCM line.\u003c\/p\u003e\n\u003cp\u003eFor the trailing twelve months ending March 31, 2025, UPC reported total revenue of \u003cstrong\u003e$19.29 million\u003c\/strong\u003e. The latest reported quarterly revenue (Q2 2025) was \u003cstrong\u003e$9.15 million\u003c\/strong\u003e, which represented a decrease of \u003cstrong\u003e-50.44%\u003c\/strong\u003e from the same quarter last year.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Months (TTM) Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.29 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnding March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.02 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year ending September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.31 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year ending September 30, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow. This is a common strategy for smaller pharma companies to maintain cash flow.\u003c\/p\u003e\n\u003cp\u003eThe company reported a net loss of \u003cstrong\u003e-$3.28 million\u003c\/strong\u003e for the last quarter (Q2 2025). The TTM net loss was \u003cstrong\u003e-$9.62 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eEasy. Competitors can sign similar agreements with other manufacturers quickly.\u003c\/p\u003e\n\u003cp\u003eThe company's total assets were reported at \u003cstrong\u003e$80.67 million\u003c\/strong\u003e and total liabilities at \u003cstrong\u003e$23.42 million\u003c\/strong\u003e as of the latest quarter.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh. This seems to be an area the company is actively using to supplement revenue.\u003c\/p\u003e\n\u003cp\u003eUniverse Pharmaceuticals INC, through its subsidiary Universe Trade, sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies alongside its own TCMD products.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProducts are sold in \u003cstrong\u003e30 provinces of China\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's employee count was \u003cstrong\u003e225\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's Debt \/ Equity ratio was \u003cstrong\u003e0.14\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone. It’s a necessary operational function, not a source of outperformance.\u003c\/p\u003e\n\u003cp\u003eThe company's Return on Equity (ROE) was \u003cstrong\u003e-23.49%\u003c\/strong\u003e on a TTM basis.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Deep Cultural Knowledge of the Chinese Elderly Healthcare Market\n\u003c\/h2\u003e\n\u003cp\u003eDeep Cultural Knowledge of the Chinese Elderly Healthcare Market\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eEssential for tailoring marketing, product claims, and regulatory navigation specific to the core demographic in China.\u003c\/p\u003e\n\u003cp\u003eThe market context includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eElderly population (60+) reached \u003cstrong\u003e264 million\u003c\/strong\u003e at the end of 2022.\u003c\/li\u003e\n\u003cli\u003eThe proportion of people aged 60 and above exceeded \u003cstrong\u003e18%\u003c\/strong\u003e by the end of 2021.\u003c\/li\u003e\n\u003cli\u003eChina Long-term Care Market revenue was \u003cstrong\u003eUSD 13,767.7 million\u003c\/strong\u003e in 2023.\u003c\/li\u003e\n\u003cli\u003eChina Elderly Care Market reached \u003cstrong\u003eUSD 3.82 Billion\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eThe silver economy reached an estimated \u003cstrong\u003eRMB 7 trillion (US$966 billion)\u003c\/strong\u003e by end-2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. While many Chinese firms serve this market, UPC’s specific focus on TCM derivatives gives it specialized insight.\u003c\/p\u003e\n\u003cp\u003eData points related to the specialized segment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYear\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth and Elderly Care Sector Share of Big Health Industry\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Long-term Care Market Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 25,329.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Out-of-Pocket Expenditure CAGR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024-2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRequired Geriatric Dept. Beds (Secondary TCM Hospitals)\u003c\/td\u003e\n\u003ctd\u003eNo less than \u003cstrong\u003e20\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCurrent Standard\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult. This is tacit knowledge built over years of operation in a specific cultural and regulatory environment.\u003c\/p\u003e\n\u003cp\u003eSupporting Financial\/Statistical Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Health Expenditure (THE) in China surged to nearly \u003cstrong\u003e7.7 trillion yuan\u003c\/strong\u003e by 2021.\u003c\/li\u003e\n\u003cli\u003ePer capita Health Expenditure increased from \u003cstrong\u003e362 yuan\u003c\/strong\u003e in 2000 to \u003cstrong\u003e5,441 yuan\u003c\/strong\u003e in 2021.\u003c\/li\u003e\n\u003cli\u003eChina Elderly Care Market CAGR projected at \u003cstrong\u003e8.79%\u003c\/strong\u003e (2025-2033).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eModerate. This knowledge is embedded in the workforce and management structure.\u003c\/p\u003e\n\u003cp\u003eOrganizational\/Regulatory Data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eArea of Embedding\u003c\/td\u003e\n\u003ctd\u003eMetric\/Target\u003c\/td\u003e\n\u003ctd\u003eReference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCM Hospital Geriatric Dept. Beds (Higher-level)\u003c\/td\u003e\n\u003ctd\u003eNo less than \u003cstrong\u003e30\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCircular Requirement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Elderly Population (60+)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e355 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2037\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Total Healthcare Market Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUSD 1.6 trillion\u003c\/strong\u003e (Estimate)\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. It erodes if the company cannot maintain market presence or if competitors hire away key personnel.\u003c\/p\u003e\n\u003cp\u003eMarket Growth Indicators:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eChina Long-term Care Market CAGR: \u003cstrong\u003e9%\u003c\/strong\u003e (2024 to 2030).\u003c\/li\u003e\n\u003cli\u003eOut-of-pocket expenditures forecasted to reach \u003cstrong\u003eUSD 568 bn\u003c\/strong\u003e by 2030.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Streamlined Post-Reorganization Capital Structure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The March 2025 share consolidation was intended to streamline the capital structure, potentially improving liquidity and making the stock more palatable to certain institutional investors. The action converted 40 pre-consolidation ordinary shares with a par value of US$0.28125 each into one ordinary share with a par value of US$11.25. The consolidation was made effective on March 24, 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePre-Consolidation (Implied\/Prior)\u003c\/th\u003e\n\u003cth\u003ePost-Consolidation (Effective March 24, 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrdinary Share Par Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$0.28125\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$11.25\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Authorized Capital\u003c\/td\u003e\n\u003ctd\u003eImplied based on prior structure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$140,625,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthorized Ordinary Shares\u003c\/td\u003e\n\u003ctd\u003eImplied based on prior structure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11,250,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthorized Preferred Shares\u003c\/td\u003e\n\u003ctd\u003eImplied based on prior structure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,250,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Corporate restructuring is common, especially when facing compliance issues. The company had a prior 15:1 consolidation in November 2024 and considered a ratio between 20:1 and 50:1 in February 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy. Other struggling firms can execute similar maneuvers, though the 40-for-1 ratio was aggressive.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management successfully executed a complex corporate action, with trading beginning on a post-Share Consolidation basis on March 24, 2025, under the same symbol “UPC” but with a new CUSIP number.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None. It’s a necessary housekeeping item, not a source of ongoing profit.\u003c\/p\u003e\n\n\u003cp\u003eRecent financial performance data relevant to the operational context surrounding the reorganization includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal revenue for the last reported quarter (Q2 2025) was \u003cstrong\u003e$9.15M\u003c\/strong\u003e, a decrease of \u003cstrong\u003e-50.44%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eNet income for Q2 2025 was \u003cstrong\u003e$-3.28M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the six months ended March 31, 2024, revenue was \u003cstrong\u003e$12.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe net loss for the six months ended March 31, 2024, was \u003cstrong\u003e$13,101,457\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash on hand as of March 31, 2024, was \u003cstrong\u003e$8,861,590\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Tangible Asset Base\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eTangible Asset Base Assessment:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe company reported total assets of \u003cstrong\u003e$80.67 million\u003c\/strong\u003e as of the latest quarter, providing a tangible floor value and collateral for operations. The balance sheet indicates total shareholder equity of \u003cstrong\u003e$55.18 million\u003c\/strong\u003e against total liabilities of \u003cstrong\u003e$25.48 million\u003c\/strong\u003e. Short term assets are reported at \u003cstrong\u003e$65.0 million\u003c\/strong\u003e, exceeding short term liabilities of \u003cstrong\u003e$23.4 million\u003c\/strong\u003e. The net change in cash for the latest quarter was \u003cstrong\u003e$17.78 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (Latest Quarter\/Date)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80.67 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.48 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$55.18 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.73 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.01%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Change in Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.78 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShort Term Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$65.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShort Term Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eLow. Other pharma companies have assets, but UPC’s are tied up in specific manufacturing\/distribution assets. The market capitalization as of November 26, 2025, was reported at \u003cstrong\u003e$2.11M\u003c\/strong\u003e, indicating a small asset base relative to many industry peers, though the absolute value exists.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate. Physical assets can be bought, but their specific location and regulatory approval status are harder to copy. The total debt-to-equity ratio is \u003cstrong\u003e14.01%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate. The assets are on the books, but the low market cap suggests they are not being fully utilized or valued by the market. The company's market capitalization has decreased by \u003cstrong\u003e-97.61%\u003c\/strong\u003e since its IPO on March 23, 2021, falling from \u003cstrong\u003e$105.00M\u003c\/strong\u003e to \u003cstrong\u003e$2.51M\u003c\/strong\u003e as of December 8, 2025. The trailing twelve months (TTM) return on investment (ROI) is \u003cstrong\u003e-23.49%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eNone. Assets are necessary, but not rare or difficult to imitate in the long run. The TTM net profit margin is \u003cstrong\u003e-37.90%\u003c\/strong\u003e. The company reported sales of \u003cstrong\u003e9.15\u003c\/strong\u003e and net income of \u003cstrong\u003e-3.28\u003c\/strong\u003e for the latest quarter.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eUPC's 52 Week high was \u003cstrong\u003e$197.20\u003c\/strong\u003e and the 52 Week low was \u003cstrong\u003e$2.51\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company was founded in \u003cstrong\u003e1998\u003c\/strong\u003e and has \u003cstrong\u003e225\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003eThe trailing twelve months (TTM) gross margin is \u003cstrong\u003e30.41%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eUniverse Pharmaceuticals INC (UPC) - VRIO Analysis: Established Brand Recognition in Niche TCM Segment\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEstablished Brand Recognition in Niche TCM Segment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides a degree of customer trust and inertia when purchasing wellness products for chronic conditions among the elderly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. Being a known entity in a specific product category is valuable, even if overall market cap is small.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult. Brand equity is built over time through consistent product quality and marketing spend.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Moderate. The brand equity is present, but recent negative news (like the Nasdaq notice) definitely tarnishes it. The company has 225 employees. Institutional Ownership stands at 0.36%.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. Brand value is highly dependent on sustained positive perception and product availability.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.02 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.29m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTrailing Twelve Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Change YoY\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-28.74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 vs. Previous Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLosses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$8.73 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.35 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e563,338\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30.41%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-49.87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe niche segment focuses on Traditional Chinese Medicine Derivatives (TCMD) products targeting chronic condition treatments and cold\/flu medications.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTCMD products include Guben Yanling Pill, Shenrong Weisheng Pill, and Fengshitong Medicinal Liquor.\u003c\/li\u003e\n\u003cli\u003eThe company received a Nasdaq staff determination notice on February 19, 2025, for failure to file the Annual Report (Form 20-F) for the fiscal year ended September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eThe company received a minimum bid price deficiency notice on October 25, 2024, with a compliance deadline of April 23, 2025, under Nasdaq Listing Rule 5550(a)(2).\u003c\/li\u003e\n\u003cli\u003eThe stock price was noted as $0.1598 as of February 25, 2025.\u003c\/li\u003e\n\u003cli\u003eA 15:1 share consolidation was effective November 12, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516271878293,"sku":"upc-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/upc-vrio-analysis.png?v=1740227391","url":"https:\/\/dcf-model.com\/fr\/products\/upc-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}